Tersus Life Sciences LLC, is a US-based bio-life science company dedicated to the research, development, and commercialization of Provinal, a naturally occurring highly purified monounsaturated fatty acid of the C16:1n7 palmitoleic class. Initially, Provinal has demonstrated a broad range of indications and applications by its lipid-lowering and anti- inflammatory effects in the management of cardiometabolic disorders, glucose metabolism and eye and tear health, bridging the treatment gap in lipid management. In preclinical, clinical and human epidemiological studies, Provinal has shown anti-inflammatory and lipid-lowering benefits linked to the prevention of metabolic syndrome, including cardiovascular disease, HDL augmentation, prevention/regression of atherosclerotic plaque, adjunctive insulin resistance therapy associated with Type II diabetes, obesity and dry eye disease associated with Meibomian gland dysfunction and poor tear production and quality. Under the trademarked name Provinal, Tersus has secured composition-of-matter and specific methods-of-use patents and patents-pending, worldwide, and will continue to do so as research continues. To Tersus' knowledge, there is no competitive product on the market or under development, nor are there other fatty acid products that possess such a broad range of pharmacological activity and potential, both GRAS and NDI certified.